|Bid||13.30 x 1400|
|Ask||23.00 x 800|
|Day's Range||16.50 - 17.04|
|52 Week Range||1.17 - 17.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.67|
Endocyte, Inc. (ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical group of companies, announced today that ITM´s subsidiary, Isotope Technologies Garching GmbH (ITG), and Endocyte have signed a long-term global supply agreement for the highly purified, no-carrier-added Lutetium-177 (177Lu) EndolucinBeta® to support clinical and commercial supply of 177Lu-PSMA-617, through 2035. “We are pleased to secure this long-term strategic partnership to ensure a reliable supply of no-carrier-added Lutetium-177 through commercialization,” said Mike Sherman, president and CEO of Endocyte. Under the terms of the supply agreement, ITG will provide Endocyte with 100% of the Lutetium-177 required for the phase 3 VISION trial.
Here are four stocks in biotech, energy and media that are breaking out on news. Endocyte Inc.(ECYT) had a strong session Tuesday, up 81 cents, or 6%, to $14.45 on 1.4 million shares traded. The biopharmaceutical company, which on Monday was added to the Russell 3000 Index, announced that an image from its Phase 2 prostate cancer study was selected as “Image of the Year” by the Society of Nuclear Medicine and Molecular Imaging.
Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that an image from a Phase 2 study of 177Lu-PSMA-617, led by Dr. Michael Hofman of the Peter McCallum Cancer Centre in Melbourne, Australia, was selected at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting as the “Image of the Year.” The image depicts the positron emissions tomography (PET) scans of eight patients before treatment with 177Lu-PSMA-617 and at three months following treatment. “This recognition reflects the potential of 177Lu-PSMA-617 and radioligand therapies to be a new treatment modality for patients with metastatic castration-resistant prostate cancer (mCRPC).” said Mike Sherman president and CEO of Endocyte.
WEST LAFAYETTE, Ind., June 25, 2018-- Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that its common stock has been selected ...
WEST LAFAYETTE, Ind., June 22, 2018-- Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that multiple presentations related ...
Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Center in Omaha, NE, a member of Precision Cancer Research. The international, prospective, open-label, multicenter, randomized phase 3 study is evaluating patients with progressive prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), who have received at least one novel androgen axis drug (abiraterone or enzalutamide) and at least one taxane regimen. “We are pleased to announce the initiation of this important clinical trial so quickly following our end-of-phase 2 meeting with the FDA.
A range of momentum stocks in biotech, technology and the cannabis industry have charts that are showing strength. Akcea Therapeutics Inc.(AKCA) rose $1.56, or 6.7%, to $24.85 Tuesday on volume of 336,400 shares, slightly below normal but the best in six sessions. The biopharmaceutical company announced it will present at the Jefferies Global Healthcare Conference on June 5.
A live audio webcast of the Company's presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference. Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section.
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Insmed Inc. (NASDAQ: INSM), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=INSM as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) for treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Endocyte Inc’s (NASDAQ:ECYT) track record on a high level, to giveRead More...
Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that a poster with data from the Peter MacCallum Cancer Centre will be presented on Endocyte’s lead investigational therapy at the 2018 ASCO Annual Meeting on Saturday, June 2, 2018. Updated data from the phase 2 study of 177Lu-PSMA-617 as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC), including data from an additional 20 patient expansion cohort, will be highlighted by the poster. “We are very pleased that we continue to see high rates of PSA response, even in heavily pre-treated patients,” said Mike Sherman, president and CEO of Endocyte.
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
The West Lafayette, Indiana-based company said it had a loss of 16 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...